Issue on combined locoregional and systemic treatment for hepatocellular carcinoma

Treatment for hepatocellular carcinoma (HCC) has been challenging as most patients present with late, advanced disease, where curative options are limited. For years, locoregional therapy (LRT) the first-line intermediate-stage HCC and sorafenib HCC. However, these treatments often palliative since they plagued by tumor recurrence or progression. Therefore, there is growing interest in combined to utilize their respective strengths produce synergistic effects. This review outlines past current research on efficacy safety of LRT systemic therapy.